Duncan Yaggy, Ph. D.
Dr. Yaggy is President of the Yaggy Corporation, managing family investments in real estate and start-ups. Dr. Yaggy worked in planning for the Duke University Medical Center for 31 years, retiring at the end of 2011 as the Associate Vice President of the Duke University Health System.
Dr. Yaggy also served as Professor of the Practice of Public Policy Studies for the Sanford School and now mentors mid-career health professionals for the Department of Family Medicine and Community Health. Earlier in his career he worked in various capacities for the Commonwealth of Massachusetts - as Assistant Commissioner of Health Regulation in the Department of Public Health and Assistant Secretary of Human Services.
Dr. Yaggy earned his BA at Yale University and his Ph.D. at Brandeis University.
Gilbert S. Mott, Jr.
Mr. Mott is a pharmaceutical and medical device executive with a 37 year career focus on respiratory pharmaceuticals and medical devices. Mr. Mott is the cofounder President and Chief Executive Officer of Concentrx Pharmaceuticals, Inc. Formerly, Mr. Mott was the founder, President, and CEO of Respirics, Inc., an inhaled pharmaceutical development company based in Raleigh, NC.
Earlier in his career, Mr. Mott served as Vice President of US Marketing for Respiratory products at Glaxo, Inc., and was later VP of Managed Markets and lastly Vice President of Managed Care at Glaxo. In 1995, Mr. Mott joined Enact Health Management Systems, later LIFECHART.com, in Mountain View, CA, makers of AirWatch, the first online personal health information system for asthmatic patients.
Mr. Mott is a graduate of the University of Miami and studied marketing at the University of California Los Angeles Anderson School of Management.
BOARD OF DIRECTORS
Indu Parikh, Ph.D.
Dr. Parikh has more than 40 years of drug discovery and development experience from both large pharma and biotech start-up companies. Dr. Parikh has held executive positions at Burroughs Wellcome and Glaxo Inc. in North Carolina. At Glaxo he played a leading role to help establish Glaxo’s R&D operation in the Research Triangle Park from ground up. Dr. Parikh, cofounded BioMarck Pharmaceuticals in 2002 and has served as its Chief Executive Officer, President, and Chief Scientific Officer. He was founder, Chief Scientific Officer and VP of R&D of RTP Pharma, a successful nanotechnology based drug delivery company, which was acquired in 2001 by SkyePharma. Dr. Parikh was educated at the University of Zurich in Switzerland, he later served as Assistant Professor of Pharmacology with a joint appointment as Assistant Professor of Medicine at Johns Hopkins School of Medicine in Baltimore, Maryland.
Dr. Parikh is currently serving as an Adjunct Professor of Cell Biology at North Carolina State University. Dr. Parikh has been on scientific and corporate advisory boards of many biotech companies. He has published more than 70 scientific publications and has been granted more than 25 U.S. patents.
Eric C. Richardson, ME
Mr. Richardson is a mechanical engineer with 25 years of experience, 16 years focused on respiratory drug delivery devices. Mr. Richardson is the cofounder Sr. Vice President and Chief Operating Officer of Concentrx Pharmaceuticals, Inc. Formerly, Mr. Richardson worked for 3M Riker Laboratories while attending University and worked as a Product Development Engineer for Bespak Ltd and Director of Product Development and Manufacturing for Respirics, Inc. in North Carolina before forming his consulting firm Syphase, LLC in 2010.
Mr. Richardson is a leading design and manufacturing engineer and the inventor of the Halix™ Unit Dose Disposable – Dry Powder Inhaler.
Mr. Richardson is a graduate of California State University Chico.
Richard C. Boucher, MD
Dr. Boucher is currently the James Moeser Eminent Professor of Medicine, Director of the Marsico Lung Institute and the UNC CF Center at the University of North Carolina at Chapel Hill. Dr. Boucher is also Co-Chairman and Co-Founder of Parion Sciences. Dr. Boucher is a world renowned expert in the area of airway epithelia and related diseases including Cystic Fibrosis. Dr. Boucher has 500 scientific publications and over 30 issued patents and has founded multiple companies including Inspire Pharmaceuticals and Parion Sciences. He serves as an editor of numerous scientific publications and as has served as advisor for several organizations.
Dr. Boucher earned his undergraduate degree from Yale University and completed his Medical Degree and Residency at Columbia University and Columbia Presbyterian Hospital. He was a Research Fellow at McGill University and completed a Residency and Fellowship at Royal Victoria Hospital in Montreal Canada.
Mr. Disbrow has over eighteen years of experience in the pharmaceutical industry with “Big Pharma” and specialty pharmaceutical companies. Mr. Disbrow currently serves as Chief Operating Officer of Aytu BioScience, a specialty pharmaceutical company focused on urologic conditions. From November 2013, Mr. Disbrow served as President & CEO of Vyrix Pharmaceuticals, until the merger to form Aytu BioScience in April 2015.
Mr. Disbrow was the Founder, President and Chief Executive Officer of Arbor Pharmaceuticals – a specialty pharmaceutical company focused initially on pediatrics. As the sole founder of Arbor he was responsible for all aspects of the company’s start-up and growth phases including fundraising, business and product development, commercial strategy, product marketing and partnering. Mr. Disbrow was also responsible for negotiating the acquisition of the company to a private investor group in 2010 and remained with the company post-acquisition as Vice President of Commercial Development. In less than five years Arbor grew from a company with no product revenues to net sales in excess of $127 million. Prior to founding Arbor Pharmaceuticals, he was head of marketing for Accentia Biopharmaceuticals, Inc. Mr. Disbrow began his career with GlaxoWellcome, Inc. (now GlaxoSmithKline plc) where he held positions of increasing responsibility in sales and marketing.
Mr. Disbrow received a BS in Business Management from North Carolina State University in Raleigh, NC.
Andrew Widmark, MBA, JD
Mr. Widmark is the CEO of Mark Properties, he has been involved with real estate and "start ups" for 30 years. Mr. Widmark was a Professor of Law at Rutgers University and a Professor of the Practice of Law at the Fuqua School of Business at Duke University.
Mr. Widmark attended Farleigh Dickinson University, he holds an MBA from the Warton School of Business at the University of Pennsylvania and JD degree from Rutgers University School of Law.